Therapeutic dosing of a neuregulin or a subsequence thereof for treatment or prophylaxis of heart failure
AssigneeAcorda Therapeutics, Inc.
InventorsAnthony O. Caggiano, Anindita Ganguly, Jennifer Iaci, Tom Parry
Life of this patent
Estimating the term…
Abstract
The invention relates to treatment of heart failure in a mammal. Accordingly, the invention is directed to establishing a dosing regimen whereby the therapeutic benefits conferred by administration of a neuregulin such as glial growth factor 2 (GGF2) or a subsequence thereof are maintained and/or enhanced, while concomitantly minimizing any potential side effects.
Claims12
A method of reducing side effects due to supraphysiological levels of a peptide comprising an epidermal growth factor-like (EGF-like) domain of glial growth factor 2 (GGF2) upon administration while treating or preventing heart failure in a mammal over a prolonged duration, said method comprising:
- administering a therapeutically effective amount of said peptide to said mammal at an interval of at least 96 hours, wherein said therapeutically effective amount is effective to reduce side effects due to supraphysiological levels of said peptide while treating or preventing heart failure in said mammal.
Dependencies are inferred from the claim text.